A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With EGFR-Positive Metastatic Solid Tumors

This was a single arm phase Ib study to evaluate the safety and efficacy of combined Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing EGFR for whom no standard treatment is available. Patients who had relapsed following their most recent line of chemotherapy and who met all other entry criteria at Screening were enrolled to receive Tomuzotuximab and Gatipotuzumab in combination.
During the extension phase, instead of Tomuzotuximab a commercially avalaible anti-EGFR antibody, i.e. Cetuximab (including any approved biosimilar), Panitumumab, or Necitumumab could be given to patients with cancers for which their use is approved.

Start Date02 Nov 2017

Sponsor / Collaborator

Glycotope GmbH

NCT01222637

/ CompletedPhase 1

Dose-escalation, PK- and Safety Study With Single Agent CetuGEX™ in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer

This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of CetuGEX™ after intravenous administration in patients with EGFR positive, locally advanced and/or metastatic solid cancers. The effect of CetuGEX™ on the development of anti-drug antibodies and on tumour response was also evaluated.

Start Date01 Aug 2010

Sponsor / Collaborator

Glycotope GmbH

100 Clinical Results associated with Tomuzotuximab

100 Translational Medicine associated with Tomuzotuximab

100 Patents (Medical) associated with Tomuzotuximab

Literatures (Medical) associated with Tomuzotuximab

01 Aug 2022·ESMO open

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’

Author: M. Kebenko ; A. Zurlo ; O. Saavedra ; M. Macchini ; F. Raspagliesi ; W.M. Fiedler ; H. Baumeister ; C. Rolling ; G. Del Conte ; S. Ochsenreither ; I. Ahrens-Fath ; U. Keilholz ; B. Habel ; A. Garralda ; D. Lorusso ; I. Matos ; K.F. Klinghammer

The publisher regrets that the authorship list was incorrectly published, the corrected list is above. The publisher would like to apologise for any inconvenience caused. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsESMO OpenVol. 7Issue 2PreviewThe phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) antibody in refractory solid tumors. Full-Text PDF Open Access

01 Apr 2022·ESMO openQ3 · MEDICINE

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Q3 · MEDICINE

ArticleOA

Author: G.D. Conte ; M. Kebenko ; A. Zurlo ; O. Saavedra ; M. Macchini ; F. Raspagliesi ; W.M. Fiedler ; H. Baumeister ; C. Rolling ; E. Garralda ; S. Ochsenreither ; I. Ahrens-Fath ; U. Keilholz ; B. Habel ; D. Lorusso ; K.F. Klinghammer ; I. Matos

BACKGROUND:

The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal antibody binding to the tumor-associated epitope of mucin 1 (TA-MUC1) and an anti-epidermal growth factor receptor (anti-EGFR) antibody in refractory solid tumors.

PATIENTS AND METHODS:

Initially the study enrolled primary phase (PP) patients with EGFR-positive metastatic solid tumors, for whom no standard treatment was available. Patients received gatipotuzumab administered at 1400 mg every 2 weeks, 6 weeks after the start of the glyco-optimized anti-EGFR antibody tomuzotuximab at 1200 mg every 2 weeks. As this regimen was proven safe, enrollment continued in an expansion phase (EP) of patients with refractory metastatic colorectal cancer, non-small-cell lung cancer, head and neck cancer and breast cancer. Tomuzotuximab and gatipotuzumab were given at the same doses and gatipotuzumab treatment started 1 week after the first dose of the anti-EGFR antibody. Additionally, investigators could use a commercial anti-EGFR antibody in place of tomuzotuximab.

RESULTS:

A total of 52 patients were enrolled, 20 in the PP and 32 in the EP. The combined treatment was well tolerated and no dose-limiting toxicity was observed in the whole study, nor related serious adverse event or death. Preliminary activity of the combination was observed, with one and four RECIST partial responses in the PP and EP, all in colorectal cancer patients. The trial was accompanied by a comprehensive translational research program for identification of biomarkers, including soluble TA-MUC1 (sTA-MUC1) in serum. In the EP, patients with baseline sTA-MUC1 levels above the median appeared to have improved progression-free survival and overall survival.

CONCLUSIONS:

Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination.

01 Oct 2021·ESMO openQ3 · MEDICINE

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study

Q3 · MEDICINE

ArticleOA

Author: B. Dietrich ; S. Rottey ; A. Zurlo ; I. Ahrens-Fath ; H. Baumeister ; K. Klinghammer ; J. Lavernia ; U. Keilholz ; A. Jacobs ; P. Debourdeau ; G. Folprecht ; J. Fayette ; P. Schafhausen ; S. Ochsenreither ; A. Kawecki ; A. Dietz

BACKGROUND:

The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal growth factor receptor (anti-EGFR) antibody tomuzotuximab against cetuximab both in combination with chemotherapy in patients with recurrent and/or metastatic squamous cell cancer of the head and neck in the first-line treatment.

PATIENTS AND METHODS:

In this phase II trial 240 patients were equally randomized for six cycles to receive either tomuzotuximab (initial dose 990 mg then 720 mg) weekly and cisplatin 100 mg/m² and fluorouracil (5-FU; 1000 mg/m²/day, days 1-4) every 3 weeks or cetuximab (400 mg/m² subsequent 250 mg/m²) weekly with the same chemotherapeutic backbone followed by antibody maintenance treatment. The primary endpoint was progression-free survival.

RESULTS:

Median progression-free survival was 6.5 months [95% confidence interval (CI) 5.9-7.9 months] in the tomuzotuximab group and 6.2 months (95% CI 5.8-7.3 months) in the cetuximab group (P = 0.86). The median overall survival (OS) estimate was 11.6 months (95% CI 9.5-17.2 months) in the tomuzotuximab group and 13.8 months (95% CI 12.3-16.4 months) in the cetuximab group (P = 0.96). In an exploratory analysis a small subgroup of p16-positive patients had a significantly longer OS compared with p16-negative patients (hazard ratio 1.860, 95% CI 1.09-3.16, P = 0.02).

CONCLUSIONS:

The glyco-engineered antibody tomuzotuximab failed to demonstrate improved efficacy with a chemotherapeutic backbone in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. It remains a so far unanswered question whether such antibody would partner better with different drugs such as checkpoint inhibitors.

News (Medical) associated with Tomuzotuximab

04 Jun 2021

·www.globenewswire.com

Glycotope Poster Presentation at the 2021 American Society

Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, June 4, 2021 - Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announced it is presenting two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually this year due to COVID-19. Henner Kollenberg, Managing Director of Glycotope GmbH commented: “The data presented at ASCO highlight our ability to draw on our long-standing expertise in glyco-biology to generate novel biopharmaceuticals targeting cancer indications. The data showed that a Glycotope-developed anti-TA-MUC1 antibody combined with the anti-EGFR Tomuzotuximab or Panitumumab in patients with refractory solid tumors is safe and feasible and exhibited interesting anti-tumour activity.” Poster details are as follows: Poster 2524Title: Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab or Panitumumab in patients with refractory solid tumorsSession: Poster Session: Developmental Therapeutics—ImmunotherapyAbstract ID: 332635 Download: Poster 2522Title: Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab or Panitumumab in patients with refractory solid tumorsSession: Poster Session: Developmental Therapeutics—ImmunotherapyAbstract ID: 329709 Download: Contact Information: About GATTO The multicenter, open label phase Ib GATTO study explored the feasibility, tolerability and preliminary activity of combining Gatipotuzumab, a novel humanized monoclonal antibody binding to a tumor-associated epitope of mucin-1 (TA-MUC1) and an anti-EGFR antibody. Based on compelling preclinical evidence suggesting a complex interaction between EGFR and TA-MUC1 expressed on the tumor cell surface in driving carcinogenesis, this study assessed the tolerability, safety and preliminary activity of targeting EGFR and TA-MUC1. In this study, 50 patients with refractory solid tumors were treated with both antibodies in 5 centers in Germany, Italy and Spain. The results analysis demonstrated that combination of TA-MUC1 and EGFR targeting antibodies is safe and feasible. Encouraging anti-tumor activity was observed in heavily pretreated NSCLC and CRC patients, particularly when the commercial anti-EGFR Panitumumab was used in combination with Gatipotuzumab. Levels of soluble TA-MUC1 may have predictive value and potentially be a companion biomarker for further development of the combination. About Glycotope Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycotope has to date discovered in excess of 150 GlycoTargets with antibodies against several of these targets currently under development.Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Currently six clinical and pre-clinical programs based on the TA-MUC1 GlycoTarget are under development by Glycotope or its licensing partners. Visit .

Small molecular drugAntibodyImmunotherapyASCO

30 Apr 2021

·www.globenewswire.com

Glycotope Announces Poster Presentations at the 2021

Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, April 30, 2021 - Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announced it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually this year due to COVID-19. Poster details are as follows: Poster 2254Title: Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab or Panitumumab in patients with refractory solid tumorsSession: Poster Session: Developmental Therapeutics—ImmunotherapyAbstract ID: 332635 Poster 2252Title: Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab or Panitumumab in patients with refractory solid tumorsSession: Poster Session: Developmental Therapeutics—ImmunotherapyAbstract ID: 329709 Due to the virtual format, all oral, poster, and poster discussion sessions, as well as track-based Clinical Science Symposia, will be available on demand, beginning 4 June 2021 at 9 a.m. EDT, for registered attendees of the conference. Contact Information: About GATTO The multicenter, open label phase Ib GATTO study explored the feasibility, tolerability and preliminary activity of combining Gatipotuzumab, a novel humanized monoclonal antibody binding to a tumor-associated epitope of mucin-1 (TA-MUC1) and an anti-EGFR antibody. Based on compelling preclinical evidence suggesting a complex interaction between EGFR and TA-MUC1 expressed on the tumor cell surface in driving carcinogenesis, this study assessed the tolerability, safety and preliminary activity of targeting EGFR and TA-MUC1 with glyco-engineered antibodies. In this study, 50 patients with refractory solid tumors were treated with both antibodies in 5 centers in Germany, Italy and Spain. The results analysis demonstrated that combination of TA-MUC1 and EGFR targeting antibody is safe and feasible. Encouraging anti-tumor activity was observed in heavily pretreated CRC and NSCLC patients. Levels of soluble TA-MUC1 may have predictive value and potentially be a companion biomarker for further development of the combination. About Glycotope Glycotope is a biotechnology company utilizing a proprietary technology platform to develop highly tumor-specific monoclonal antibodies called GlycoBodies. GlycoBodies bind to targets (GlycoTargets) tumor-specific carbohydrate structure dependent, enabling the development of highly-specific immunotherapies across a broad range of cancer indications. Glycotope has to date discovered in excess of 150 GlycoTargets with GlycoBodies against eight of these targets currently under development. Each GlycoBody can be developed in an array of modalities with different modes of action such as Antibody-drug conjugates, CAR/cell therapies or bispecifics, providing a unique offering in the (immuno) oncology space. Currently six clinical and pre-clinical programs based on the GlycoBody technology are under development by Glycotope or its licensing partners. Visit .

AntibodyCollaborateCell TherapyImmunotherapyADC

30 Jul 2018

·www.daiichisankyo.com

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

PDF (242KB)PDF For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Sunao Manabe, Representative Director, President and COO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Koji Ogawa, Corporate Officer, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 https://www.daiichisankyo.com Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX®), building on a previous 2017 option agreement. Under the terms of the licensing agreement, Daiichi Sankyo has worldwide exclusive rights to develop and commercialize gatipotuzumab as an ADC. Glycotope will receive an upfront payment and is eligible for clinical, regulatory and sales milestone payments, as well as royalties on net sales worldwide from Daiichi Sankyo. Specific financial terms have not been disclosed. “With the licensing of gatipotuzumab with the intention of developing an ADC, we now have seven novel ADCs in development, which demonstrate our commitment to maximizing the potential of our proprietary ADC payload and linker technology to help address the unmet needs of patients with cancer worldwide,” said Tom Held, Vice President, Head, Antibody Drug Conjugate Task Force, Oncology Research and Development, Daiichi Sankyo. “We are excited by the rapid progress we have made in our collaboration with Glycotope and look forward to the continued clinical development of this potentially first-in-class TA-MUC1-targeting ADC.” “This agreement with Daiichi Sankyo highlights the potential and wide applicability of gatipotuzumab,” said Henner Kollenberg, Managing Director of Glycotope. “Our world-leading glyco-biology expertise has allowed us to create a novel anti-TA-MUC1 monoclonal antibody with carbohydrate mediated tumor-specificity and high affinity binding. We look forward to continuing to work with Daiichi Sankyo on this ADC program and on the further development of gatipotuzumab in other formats.” ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Daiichi Sankyo’s proprietary ADC technology is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered. Gatipotuzumab is an investigational monoclonal antibody that enables tumor-specific binding to a novel carbohydrate-induced conformational epitope, TA-MUC1, which is extensively expressed in many tumor types including ovarian, lung and breast.1 About Glycotope Glycotope is a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise. The company draws on its long experience in glyco-biology to create highly specific mAbs targeting glyco-epitopes, and glyco-optimized mAbs with enhanced performance. Glycotope has a growing pipeline of high-value cancer therapies focused around the glyco-optimized antibody, gatipotuzumab, which targets the novel glyco-epitope target TA-MUC1. Its lead clinical program is in phase 1b in combination with tomuzotuximab, a glyco-optimized second-generation anti-EGFR mAb. Glycotope has entered a partnership with Daiichi Sankyo for antibody drug conjugates (ADCs) and is also exploring multiple additional formats based on gatipotuzumab. Visit http://www.glycotope.com/Open new window.. About Daiichi Sankyo Cancer Enterprise The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science, we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025. Our powerful research engines include two laboratories for biologic/immuno-oncology and small molecules in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. Compounds in pivotal stage development include: DS-8201, an antibody drug conjugate (ADC) for HER2-expressing breast, gastric and other cancers; quizartinib, an oral selective FLT3 inhibitor, for newly-diagnosed and relapsed/refractory FLT3-ITD acute myeloid leukemia (AML); and pexidartinib, an oral CSF1R inhibitor, for tenosynovial giant cell tumor (TGCT). For more information, please visit: www.DSCancerEnterprise.comOpen new window.. About Daiichi Sankyo Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.comOpen new window.. Contact Daiichi Sankyo: Jennifer Brennan Daiichi Sankyo, Inc. jbrennan2@dsi.com +1 908 992 6631 (office) +1 201 709 9309 (mobile) Glycotope: Henner Kollenberg Glycotope GmbH contact@glycotope.com +49 30 9489 2600 References: 1. Fidler W, et al. Eur J Cancer. 2016; 63:55-63.

License out/inADCPhase 1Immunotherapy

100 Deals associated with Tomuzotuximab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC06	DB15178

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Squamous cell carcinoma of head and neck metastatic	Phase 2	Belgium	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	France	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	Germany	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	Italy	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	Poland	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	Romania	Glycotope GmbH	01 Feb 2014
Squamous cell carcinoma of head and neck metastatic	Phase 2	Spain	Glycotope GmbH	01 Feb 2014
EGFR mutation Solid Tumors	Phase 1	Germany	Glycotope GmbH	02 Nov 2017
EGFR mutation Solid Tumors	Phase 1	Italy	Glycotope GmbH	02 Nov 2017
EGFR mutation Solid Tumors	Phase 1	Spain	Glycotope GmbH	02 Nov 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02052960 (RESGEX, CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic \| Squamous Cell Carcinoma of Head and Neck	240	CetuGEX (CetuGEX)	kbqukotfll(apvylcmwri) = qbgkezqyht qzgrnhankf (aapikushpc, vddirehmhk - fanteyytcc) View more	-	02 Nov 2021
				Cetuximab (Cetuximab)	kbqukotfll(apvylcmwri) = vqevtsmlly qzgrnhankf (aapikushpc, gbhsnlctsr - xirzzegeot) View more
NCT03360734 (GATTO, ASCO 12021 \| ASCO 22021) Manual	Phase 1	Refractory Malignant Solid Neoplasm	52	gatipotuzumab+tomuzotuximab (primary phase)	ygnwohcrer(sosxrffvtm) = yxdwhelpll yjlsuwunsr (jspwsapffp ) View more	Positive	20 May 2021
				gatipotuzumab+tomuzotuximab (expansion phase)	ygnwohcrer(sosxrffvtm) = btczcqovqy yjlsuwunsr (jspwsapffp ) View more
NCT03360734 (GATTO, ESMO_GI2019)	Phase 1	EGFR mutation Solid Tumors \| Colorectal Cancer EGFR positive \| K-RAS WT	20	Tomuzotuximab	imsmfhpwcl(axomlpddfu) = hdxxkavnsu zibnasaefi (rbkqukxpxy ) View more	Positive	03 Jul 2019
NCT01222637 (Pubmed \| ESMO Open) Manual	Phase 1	Neoplasms	41	tomuzotuximab	jtgnqwttqc(mqqgoztzpe) = 1patient NSCLC bdmxghphmg (chzovnnujp ) View more	Positive	01 Feb 2018
NCT02052960 (RESGEX, ASCO_SITC2018)	Phase 2	Recurrent Squamous Cell Carcinoma of the Head and Neck Maintenance	240	CetuGEX	bvkavstsgz(yeupyrucoy) = uezzjbkwdj vrxxtflrvn (dhwbdwqduo )	Negative	25 Jan 2018
				Cetuximab	bvkavstsgz(yeupyrucoy) = njovdlwhey vrxxtflrvn (dhwbdwqduo )
NCT02052960 (RESGEX, ASCO_SITC2018)	Phase 2	Recurrent Squamous Cell Carcinoma of the Head and Neck Maintenance EGFR \| p16+ \| FcγRIIIa ... View more	240	CetuGEX	kvhmymeaut(zgqlhlmkla): HR = 0.52 (95% CI, 0.29 - 0.86), P-Value = 0.009	Positive	25 Jan 2018
				Cetuximab
NCT01222637 (ASCO2013)	Phase 1	-	41	CetuGEX	lvkuvjqiuc(itkonazgkw) = reduced as sign of redistribution ydqxjwjnqn (vtabpoyybo ) View more	-	20 May 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis